Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Mar;160(4):1131-1139.
doi: 10.1053/j.gastro.2020.11.038. Epub 2020 Nov 21.

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Uma Mahadevan  1 , Millie D Long  2 , Sunanda V Kane  3 , Abhik Roy  4 , Marla C Dubinsky  5 , Bruce E Sands  5 , Russell D Cohen  6 , Christina D Chambers  7 , William J Sandborn  8 ; Crohn’s Colitis Foundation Clinical Research Alliance
Affiliations
Observational Study

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Uma Mahadevan et al. Gastroenterology. 2021 Mar.

Abstract

Background & aims: Pregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussions to mother and child.

Methods: Between 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of 5 outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infant infections) among pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were used to determine the independent effects of specific drug classes on outcomes of interest.

Results: Among 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n = 379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infections during the first year of life. Higher disease activity was associated with risk of spontaneous abortion (hazard ratio, 3.41; 95% confidence interval, 1.51-7.69) and preterm birth with increased infant infection (odds ratio, 1.73; 95% confidence interval, 1.19-2.51).

Conclusions: Biologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or in the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy-related adverse events. ClinicalTrials.gov, Number: NCT00904878.

Keywords: Crohn’s Disease; Pregnancy; Ulcerative Colitis.

PubMed Disclaimer

References

    1. Ananthakrishnan AN KG, Ng SC. Changing Global Epidemiology of Inflammatory Bowel Diseases-Sustaining Healthcare Delivery into the 21st Century. Clin Gastroenterol Hepatol 2020. - PubMed
    1. Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133:1106–12. - PubMed
    1. Norgard B, Hundborg HH, Jacobsen BA, et al. Disease Activity in Pregnant Women With Crohn’s Disease and Birth Outcomes: A Regional Danish Cohort Study. Am J Gastroenterol 2007;102:1947–54. - PubMed
    1. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology 2002;65:240–61. - PubMed
    1. Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. The American journal of gastroenterology 2013;108:433–40. - PubMed

Publication types

MeSH terms

Associated data